|
PCBP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.04230000186334E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.94999999481027E-08 |
| Normal-vs-Stage2 |
7.597600E-03 |
| Normal-vs-Stage3 |
1.16510000536252E-08 |
| Normal-vs-Stage4 |
2.27289999998881E-06 |
| Stage1-vs-Stage2 |
8.383700E-02 |
| Stage1-vs-Stage3 |
4.677800E-01 |
| Stage1-vs-Stage4 |
8.799800E-01 |
| Stage2-vs-Stage3 |
4.334300E-02 |
| Stage2-vs-Stage4 |
1.560390E-01 |
| Stage3-vs-Stage4 |
7.134000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.40570005530338E-09 |
| Normal-vs-AfricanAmerican |
3.976000E-03 |
| Normal-vs-Asian |
8.48850001400336E-09 |
| Caucasian-vs-AfricanAmerican |
3.064200E-01 |
| Caucasian-vs-Asian |
3.194200E-01 |
| AfricanAmerican-vs-Asian |
7.098300E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.13289999998023E-06 |
| Normal-vs-Female |
5.07590003362424E-09 |
| Male-vs-Female |
3.513200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.08420000147314E-08 |
| Normal-vs-Age(41-60Yrs) |
4.6975999756782E-09 |
| Normal-vs-Age(61-80Yrs) |
5.82339999999348E-05 |
| Normal-vs-Age(81-100Yrs) |
1.162590E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.300400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.928300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.830000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.174240E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.768800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.371800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.123720E-02 |
| Classical-VS-Follicular |
1.296370E-01 |
| Classical-VS-Other |
7.899000E-01 |
| Classical-VS-Normal |
8.59119997365099E-09 |
| Tall-VS-Follicular |
1.822000E-03 |
| Tall-VS-Other |
3.807000E-01 |
| Tall-VS-Normal |
1.93539995141379E-09 |
| Follicular-VS-Other |
4.937600E-01 |
| Follicular-VS-Normal |
6.361800E-04 |
| Other-VS-Normal |
8.279100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.43970000032745E-07 |
| Normal-vs-N1 |
1.53039803052479E-11 |
| N0-vs-N1 |
1.501640E-03 |
|
|
